Pacira BioSciences, Inc. (PCRX) Dividend History

Company News

• Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

  Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors of DoubleVerify, NAPCO, Pacira Biosciences, and Treace Medical Concepts.

  GlobeNewswire Inc.

  Featured Companies: DV NSSC TMCI
• PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX

  Pacira BioSciences, Inc. is facing a securities class action lawsuit due to alleged false and/or misleading statements about the patent protection of its drug Exparel, which led to investor losses.

  GlobeNewswire Inc.
• DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

  Faruqi & Faruqi, LLP is investigating potential claims against Pacira BioSciences, Inc. (NASDAQ: PCRX) after the company's '495 patent was invalidated, leading to a significant drop in its stock price.

  GlobeNewswire Inc.
• Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Pacira BioSciences, Inc. announced the granting of inducement awards to six new employees, including stock options and restricted stock units, as a material inducement to their employment with the company.

  GlobeNewswire Inc.
• PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

  Pacira BioSciences, Inc. is facing a class action lawsuit due to its failure to disclose material information during the class period, resulting in a significant drop in its stock price.

  GlobeNewswire Inc.